SEATTLE, WASHINGTON--(Marketwire - Dec. 18, 2012) - VentriPoint Diagnostics (TSX VENTURE:VPT) (OTCQX:VPTDF) exhibited at the Annual Meeting of EUROECHO & other Imaging Modalities 2012 from December 5th to 8th in Athens, Greece. The Company had an excellent reception at the EuroEcho conference with hundreds of ultrasound healthcare professionals viewing or even using the new "Angelo" (VMS™) system, as it was setup in the Toshiba Medical System exhibition booth. With over 8 exhibits at conferences this year, the Company has had a highly successful first year of launching the Angelo (VMS™) product, with the total interested European customers now over 400, and an installed base of 26 hospitals in Europe and North America. Furthermore, VentriPoint received 2 sales orders while exhibiting at EuroEcho 2012.
VentriPoint also introduced a new prototype arm that attaches to the cart and eliminates the need for a dedicated bed. This was also on display in the Toshiba Medical Systems booth. The new addition was a welcome improvement for VentriPoint's current customers looking for a portable system, and especially important for those potential customers who have restricted space in their echo labs.
"I cannot begin to express how overjoyed I am with our success at EuroEcho", said Amol Karnick, Vice President of Sales and Business Development, "This was the first time we co-exhibited in another vendor's booth, and it was clearly successful for both of us".
VentriPoint continues to gain momentum throughout Europe, and during EuroEcho identified additional distributors for the product in various regions of Europe, including Greece and Italy and a potential distributor for the Middle East.
EUROECHO 2012 is one of the largest echo and imaging meetings in the World and is expected to attract more than 3,000 cardiologists, internists, cardiac surgeons and sonographers from over 90 countries. This year promises four days of the latest science and treatment monitoring options in cardiovascular imaging. Nearly 700 original scientific abstracts will be presented by international scientists on hot topics such as increasing the viability of hearts for transplantation, cardiovascular risks in patients with HIV, the links between obstructive sleep apnea and heart disease, and assessing the cardiac damage induced by cancer drugs.
About VentriPoint Diagnostics Ltd.
VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease in children and adults and pulmonary arterial Hypertension are the first applications in a suite of applications for all major heart diseases including cardiovascular disease and heart failure - a multi-billion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS™ diagnostic tool and the Company is pursuing the US-FDA marketing clearance through the 510(k) process.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.